Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

The pharmaceutical giant just extended the lifespan of one of its top drugs.

The news is the latest example of the biotech industry's struggles in the Bay Area.

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...